GRI Bio, Inc. (GRI)
Automate Your Wheel Strategy on GRI
With Tiblio's Option Bot, you can configure your own wheel strategy including GRI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GRI
- Rev/Share 0.0
- Book/Share 21.9996
- PB 0.0591
- Debt/Equity 0.0295
- CurrentRatio 3.4322
- ROIC -1.9839
- MktCap 3051451.0
- FreeCF/Share -46.9838
- PFCF -0.3544
- PE -0.029
- Debt/Assets 0.0207
- DivYield 0
- ROE -2.1585
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GRI | H.C. Wainwright | -- | Buy | -- | $10 | Dec. 9, 2024 |
News
GRI Bio to Participate in the Virtual Investor Closing Bell Series
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Live webcast on Wednesday, May 28 th at 4:00 PM ET LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Wednesday, May 28, 2025 at 4:00 PM ET. As part of the event, Dr. Hertz will provide a corporate overview and business outlook.
Read More
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21 st at 2:40 PM ET
Read More
GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed
Read More
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient enrollment and topline results expected Q3 2025 LA JOLLA, CA, May 07, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that enrollment for the 6 week interim analysis is complete with 24 of the 36 planned …
Read More
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
GRI stock plunges on the pricing of its public offering, paring the gains witnessed following positive IPF study results.
Read More
GRI Bio Announces Pricing of $5.0 Million Public Offering
Published: April 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
LA JOLLA, CA, April 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of a public offering of an aggregate of 1,388,888 shares of its common stock (or common stock equivalents in lieu thereof), Series E-1 warrants to purchase up to 1,388,888 shares of common stock, short-term Series E-2 warrants to purchase up to 1,388,888 shares of common stock and short-term Series E-3 warrants to purchase up …
Read More
Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?
Published: April 01, 2025 by: Benzinga
Sentiment: Positive
GRI Bio, Inc. GRI stock is trading on Tuesday with a strong session volume of 6.9 million compared to an average volume of 17.35K, as per data from Benzinga Pro.
Read More
GRI Bio Participates in a Virtual Investor CEO Connect Segment
Published: March 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Access the CEO Connect segment here
Read More
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
On-demand video webcast now available here
Read More
About GRI Bio, Inc. (GRI)
- IPO Date 2021-02-10
- Website https://www.gribio.com
- Industry Biotechnology
- CEO Dr. W. Marc Hertz Ph.D.
- Employees 3